Gilis-Segers SRL
Gilis-Segers reported total assets of 545,887 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Jul 2026).
The score of Gilis-Segers shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1 % Total assets -1 %
Accounts of the company itself (not consolidated).
The full file covers 14 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Gilis-Segers's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 29,865 € | ||||
| Equity | 385,384 € | ||||
| Cash | 217,610 € | ||||
| EBITDA | 63,636 € | ||||
| Total assets | 545,887 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jul 2026
- Year ended 31 Dec 2024filed on 04 Aug 2025
- Year ended 31 Dec 2023filed on 16 Jul 2024
- Year ended 31 Dec 2022filed on 01 Jun 2023
- Year ended 31 Dec 2021filed on 02 Jun 2022
Gilis-Segers's financial analysis
- Solvency70.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Gilis-Segers
Gilis-Segers's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0459.276.588
- VAT number
- BE0459276588
- Peppol
- Registered · 0208:0459276588 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Nov 1996
- Registered office
- 3300 Tienen
- Latest accounts
- 2025 · filed on 28 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Gilis-Segers (SRL) has been based in Tienen since 1996, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 29,865 € and equity of 385,384 €; its revenue is not published. Its solvency stands at 70.6%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Gilis-Segers
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Boden Retail sale of pharmaceutical products Essen · balance sheet 545,528 €
- Pharmacie Fryderyk Retail sale of pharmaceutical products Courcelles · balance sheet 546,723 €
- Verbofar Retail sale of pharmaceutical products Deinze · balance sheet 548,560 €
- Cassipharma Retail sale of pharmaceutical products Ghent · balance sheet 548,988 €
- APLV Retail sale of pharmaceutical products Bornem · balance sheet 542,377 €
- De Nil Retail sale of pharmaceutical products Dendermonde · balance sheet 551,344 €
- ST Farma Retail sale of pharmaceutical products Ghent · balance sheet 539,584 €
- Naveau-Smeets Retail sale of pharmaceutical products Lint · balance sheet 552,659 €
Frequently asked questions about Gilis-Segers
What is the revenue of Gilis-Segers?
Gilis-Segers files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Gilis-Segers?
In Belgium, the VAT number is the company number prefixed with BE: BE0459276588 for Gilis-Segers, if the company is VAT-registered. Its company number (CBE) is 0459.276.588.
Where is the registered office of Gilis-Segers?
According to the CBE register, the registered office of Gilis-Segers is in 3300 Tienen.
What is the equity of Gilis-Segers?
At the close of the 2025 financial year, the equity of Gilis-Segers amounts to 385,384 €, a solvency of 70.6% of total assets.
Who manages Gilis-Segers?
The register lists 2 active mandates at Gilis-Segers. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Gilis-Segers
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →